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Sensorimotor gating and attentional set-shifting are improved by
the μ-opioid receptor agonist morphine in healthy human
volunteers
Abstract
Prepulse inhibition (PPI) of the acoustic startle response (ASR) has been established as an operational
measure of sensorimotor gating. Animal and human studies have shown that PPI can be modulated by
dopaminergic, serotonergic, and glutamatergic drugs and consequently it was proposed that impaired
sensorimotor gating in schizophrenia parallels a central abnormality within the corresponding
neurotransmitter systems. Recent animal studies suggest that the opioid system may also play a role in
the modulation of sensorimotor gating. Thus, the present study investigated the influence of the μ-opioid
receptor agonist morphine on PPI in healthy human volunteers.
Eighteen male, non-smoking healthy volunteers each received placebo or 10 mg morphine sulfate (p.o.)
at a two week interval in a double-blind, randomized, and counterbalanced order. PPI was measured 75
min after drug/placebo intake. The effects of morphine on mood were measured by the Adjective Mood
Rating Scale and side effects were assessed by the List of Complaints. Additionally, we administered a
comprehensive neuropsychological test battery consisting of tests of the Cambridge Neuropsychological
Test Automated Battery and the Rey Auditory Verbal Learning Test.
Morphine significantly increased PPI without affecting startle reactivity or habituation. Furthermore,
morphine selectively improved the error-rate in an attentional set-shifting task but did not influence
vigilance, memory, or executive functions.
These results imply that the opioid system is involved in the modulation of PPI and attentional
set-shifting in humans and they raise the question whether the opioid system plays a crucial role also in
the regulation of PPI and attentional set-shifting in schizophrenia.
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Abstract 
Prepulse inhibition (PPI) of the acoustic startle response (ASR) has been established as an operational 
measure of sensorimotor gating. Animal and human studies have shown that PPI can be modulated by 
dopaminergic, serotonergic, and glutamatergic drugs and consequently it was proposed that impaired 
sensorimotor gating in schizophrenia parallels a central abnormality within the corresponding 
neurotransmitter systems. Recent animal studies suggest that the opioid system may also play a role in 
the modulation of sensorimotor gating. Thus, the present study investigated the influence of the μ-
opioid receptor agonist morphine on PPI in healthy human volunteers. 
Eighteen male, non-smoking healthy volunteers each received placebo or 10 mg morphine sulfate 
(p.o.) at a two week interval in a double-blind, randomized, and counterbalanced order. PPI was 
measured 75 min after drug/placebo intake. The effects of morphine on mood were measured by the 
Adjective Mood Rating Scale and side effects were assessed by the List of Complaints. Additionally, 
we administered a comprehensive neuropsychological test battery consisting of tests of the Cambridge 
Neuropsychological Test Automated Battery and the Rey Auditory Verbal Learning Test. 
Morphine significantly increased PPI without affecting startle reactivity or habituation. Furthermore, 
morphine selectively improved the error-rate in an attentional set-shifting task but did not influence 
vigilance, memory, or executive functions. 
These results imply that the opioid system is involved in the modulation of PPI and attentional set-
shifting in humans and they raise the question whether the opioid system plays a crucial role also in 
the regulation of PPI and attentional set-shifting in schizophrenia. 
 
Keywords: Prepulse inhibition, acoustic startle response, sensorimotor gating, morphine, 
schizophrenia, μ-opioid receptor, CANTAB. 
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Introduction 
Prepulse inhibition (PPI) of the acoustic startle response (ASR) is used as an operational measure of 
sensorimotor gating that is proposed to reflect the ability to regulate sensory input by filtering out 
irrelevant or distracting stimuli in order to prevent sensory information overflow (Braff et al., 1978; 
Braff et al., 1992). PPI refers to the reduction of the startle response when a distinctive weak 
prestimulus is presented 30 to 500 ms before a startle-eliciting stimulus (Graham, 1975). 
In accordance with the filter deficit model of schizophrenia, diminished sensorimotor gating has been 
consistently demonstrated in patients with schizophrenia (Braff et al., 1978; Braff et al., 1992; Kumari 
et al., 2000; Ludewig et al., 2003; Parwani et al., 2000; Quednow et al., 2006c). It has been 
hypothesized that the cognitive deficits and the positive symptoms in schizophrenia are related to the 
deficient sensorimotor gating (Braff et al., 2001). 
In rats schizophrenia-like PPI deficits can be induced by direct and indirect dopamine (DA) receptor 
agonists, serotonin-2A (5-HT2A) receptor agonists, and N-methyl-D-aspartate (NMDA) antagonists 
(for review see Geyer et al., 2001). Given that drug-induced PPI-deficits can be abolished by pre- or 
posttreatment with antipsychotics, it was proposed that impaired sensorimotor gating in schizophrenia 
parallels central neurochemical abnormalities underlying the disease (Geyer et al., 2001). In addition, 
evidence from cross-sectional and longitudinal clinical studies suggest that atypical antipsychotics are 
especially effective in improving deficient PPI in schizophrenia patients (Kumari et al., 1999; Kumari 
et al., 2002; Leumann et al., 2002; Oranje et al., 2002; Quednow et al., 2006c). Similarly, the atypical 
antipsychotics clozapine and quetiapine also enhance PPI in healthy human volunteers exhibiting low 
baseline PPI levels (Swerdlow et al., 2006; Vollenweider et al., 2006). Consequently, drug-induced 
PPI deficits have been established as a translational model of antipsychotic activity (Swerdlow and 
Geyer, 1998).  
Although the role of the dopaminergic, serotonergic, and glutamatergic neurotransmitter systems with 
respect to PPI is well investigated, the contribution of other neurotransmitter systems – such as the 
opioid system – in the modulation of PPI is unclear. However, the investigation of the involvement of 
the opioid system in sensorimotor gating is of special interest because the opioid system may 
participate in the pathogenesis of schizophrenia (Bloom et al., 1976; Jacquet and Marks, 1976; 
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Schmauss and Emrich, 1985; Terenius et al., 1976). Moreover, the opioid and dopaminergic reward 
system and the cortico-striato-pallido-thalamic (CSPT) circuitry involved in the regulation of PPI 
show a considerable anatomical overlap (Swerdlow et al., 1999). Nevertheless, the influence of the 
opioid system on PPI is not well-studied in animals and studies in humans are currently lacking. 
Recently, it has been shown that the selective κ-opioid receptor agonist U50488 disrupts PPI in rats 
and clozapine prevented this disruption. Moreover, the selective κ-opioid receptor antagonist 
norbinaltorphimine also prevented the U50488-induced PPI deficit, whereas norbinaltorphimine alone 
did not alter PPI (Bortolato et al., 2005). Although the μ-opioid receptor agonists morphine and heroin 
did not significantly alter PPI in rats (Leitner, 1989; Ouagazzal et al., 2001; Swerdlow et al., 1991), 
heroin clearly tended to increase PPI dose-dependently (Swerdlow et al., 1991). In mice, the 
endogenous μ-opioid receptor agonist endomorphin-1 on its own also did also not alter PPI but 
attenuated PPI deficits induced by the direct dopamine receptor agonist apomorphine (Ukai and 
Okuda, 2003). Finally, the non-selective μ-, δ-, and κ-opioid receptor antagonist naloxone did not 
influence PPI in rats but prevented the loss of PPI induced by the indirect dopamine agonist 
amphetamine, whereas apomorphine-induced PPI deficits were not altered by naloxone. The authors 
concluded that dopamine-opioid interactions in the nucleus accumbens could possibly account for 
these results (Swerdlow et al., 1991). Summarized, previous animal data did not provide a clear 
picture with respect to the role of the opioid system for sensorimotor gating.  
The involvement of the opioid system in higher cognitive functions is – apart from reward 
mechanisms and pain modulation – not well-understood (Gianoulakis, 2004; McNally and Akil, 2002; 
Waldhoer et al., 2004). Nevertheless, there is some evidence that activation of the μ-opioid receptor by 
[D-Ala(2), N-Met-Phe(4), Gly(5)]-enkephalin (DAMGO) impairs working memory in mice which can 
be reversed by the κ-opioid receptor agonist dynorphin (Itoh et al., 1994). Dynorphin also improves 
memory dysfunction in animal models of amnesia and these effects can be reversed by 
norbinaltorphimine (Ilyutchenok and Dubrovina, 1995; Ukai et al., 1997). In vitro studies on 
hippocampal neurons showed that opioids acting on the μ-opioid receptor facilitate the induction of 
long-term potentiation (LTP) of synaptic transmission which has been postulated as a cellular 
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mechanism for learning and memory. In contrast, the κ-opioid receptor agonists dynorphin and 
U50488 inhibit LTP (Simmons and Chavkin, 1996; Wagner et al., 1993; Weisskopf et al., 1993). 
However, μ-opioid receptor agonists do not generally impair cognitive functioning in humans (for 
review see Ersek et al., 2004). Only high doses of selective μ-opioid receptor agonists seem to 
decrease delayed verbal memory performance in healthy humans (Cleeland et al., 1996; Hanks et al., 
1995; Kerr et al., 1991), whereas short-term memory or working memory as well as other cognitive 
domains remained widely unimpaired even after high doses (Cleeland et al., 1996; Evans and Smith, 
1964; Hanks et al., 1995; Hill and Zacny, 2000; O'Neill et al., 2000; Walker and Zacny, 1998). On the 
contrary, some studies in healthy volunteers have shown that morphine and codeine (which is 
metabolized into morphine) increase the accuracy in choice reaction time tasks (Hanks et al., 1995; 
O'Neill et al., 2000), enhance perceptual speed and logical reasoning (Evans and Smith, 1964), and 
improve learning and delayed recall in a serial learning task (Liljequist, 1981). Interestingly, naloxone 
impaired delayed recall while decreasing learning, immediate recall, accuracy of spatial orientation, 
monitoring of word presentations, and increasing choice reaction time (Cohen et al., 1983; Martin del 
Campo et al., 1992). 
Since the role of μ-opioid receptors in the modulation of sensorimotor gating has not been studied in 
humans so far, we investigated the effects of the μ-opioid receptor agonist morphine on PPI, startle 
reactivity and habituation of ASR in healthy human volunteers in a randomized, double-blind, 
placebo-controlled, and counterbalanced design. In addition, we administered a comprehensive 
neuropsychological test battery to explore the effects of morphine on higher cognitive functions and to 
further investigate whether morphine-induced changes in sensorimotor gating are associated with 
changes in cognitive performance. Based on the finding that heroin tended to increase PPI in rats 
(Swerdlow et al., 1991), we expected to find an enhancing effect of morphine on PPI in human 
volunteers. While previous human studies found impaired delayed recall performance only after high 
doses and reported no or enhancing effects on several cognitive domains after low and moderate doses 
of morphine, we anticipated no significant effect on neuropsychological performance by the relatively 
low dose of morphine sulfate (10 mg) administered in the present study. 
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Method 
Participants 
Since menstrual cycle and smoking have been shown to influence PPI (Duncan et al., 2001; Kumari 
and Gray, 1999; Swerdlow et al., 1997) only male non-smoking subjects were included. Eighteen 
healthy volunteers (aged 19-31 years) were recruited through internet advertisement from local 
universities. Subjects’ physical health was confirmed by medical history, clinical examination, 
electrocardiography, and blood analysis. To ensure mental health, all subjects underwent a psychiatric 
screening interview based on the DIA-X computerized diagnostic expert system (Wittchen and Pfister, 
1997). Furthermore, subjects were examined with the Freiburg Personality Inventory (FPI) 
(Fahrenberg et al., 1984) and the Hopkins Symptom Checklist (SCL-90-R) (Derogatis, 1977); scores 
differing two standard deviations from the mean value of normative data in any subscale of these 
questionnaires were used as exclusion criteria (no subjects had to be excluded by these criteria). All 
subjects were also screened for hearing impairment by means of a brief hearing test. The 
demographical data are shown in Table 1. 
None of the subjects had a past or present psychiatric or neurological disorder, or a severe physical 
illness. Moreover, none of them reported a family history of psychiatric disorders, which are known to 
have an impact on PPI, specifically schizophrenia spectrum disorders or obsessive-compulsive 
disorder. All participants negated use of psychotropic medication or illicit drug use, which was 
confirmed by urine toxicologies on both test days.  
This study was approved by the Ethics Committee of the University Hospital of Psychiatry, Zurich. 
After receiving a written and oral description of the aim of this study, all participants gave written 
informed-consent statements before inclusion. 
 
******* Insert Table 1 ******* 
 
Morphine 
Morphine (Sevredol™) was obtained from Mundipharma, Basel, Switzerland and was prepared as 
gelatine capsules of 10 mg morphine sulfate (equivalent to 7.5 mg morphine) at the pharmacy of the 
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Psychiatric University Hospital Zurich. Lactose placebo and morphine were administered in gelatine 
capsules of identical appearance.  
 
Study Design 
The study design was double-blind, placebo-controlled and included two experimental conditions 
(morphine and placebo). All subjects received placebo and a single dose of morphine in a randomized 
and counterbalanced order at one of two experimental days separated by a 2-week interval. 
Sessions were conducted in a calm and comfortable laboratory environment. Participants were told to 
abstain from alcohol the day prior to each test session, not to drink caffeine-containing beverages and 
not to eat six hours prior to each session. Thirty minutes after arriving in the laboratory, subjects 
received placebo or morphine in capsules. Heart rate and blood pressure were recorded 10 min before 
as well as 65 and 160 min after drug/placebo intake. To coincide with the mean peak effects of 
morphine (Collins et al., 1998) startle measures were obtained 75 min after drug/placebo intake. The 
neuropsychological test battery was conducted directly after the startle measurement (~100 min after 
drug/placebo intake) and lasted about 45 min. The Adjective Mood Rating Scale (AMRS) (Janke and 
Debus, 1978) was administered 10 min before and 70 min after drug/placebo intake. Finally, the List 
of Complaints (von Zerssen, 1971) was assessed about 165 min after drug/placebo intake. After the 
acute drug effects of morphine subsided completely and the participants reported well-being, they 
were dismissed.  
 
Startle Response Measurement 
The eye-blink component of the acoustic startle response was measured using an EMG startle system 
(EMG-SR-LAB, San Diego Instruments, Inc., San Diego, CA). Two silver/silver-chloride electrodes 
were placed below the right eye over the orbicularis oculi muscle and a ground electrode was placed 
on the glabella. All electrode resistances were < 5 kΩ. A square wave calibrator established sensitivity 
to be 0.38 µV/digital unit. The system recorded 600 samples at 1 kHz sampling rate. EMG data were 
band-pass filtered 100 to 1000 Hz by the acquisition hardware. Acoustic startle stimuli were presented 
through headphones (TDH-39-P, Maico, Minneapolis, MN). Subjects were seated comfortably in an 
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armchair, instructed to relax, and told that they would hear a sequence of white noise bursts. They 
were asked to stay awake while staring at a fixed point (passive attention paradigm). Each session 
began with a 2-min acclimation period of 70-dB background noise that continued throughout the 
session. The session consisted of a total of 73 trials separated by inter-trial intervals varying between 
10 and 20 seconds. The trials consisted of four conditions: 115-dB pulse-alone (PA-115) trials of 40 
ms duration; 86-dB prepulse-alone (PPA-86) trials of 20 ms duration, prepulse-pulse (PP) trials 
consisting of a PA-115 shortly preceded by a PPA-86, and a non-stimulus condition (NS). All stimuli 
consisted of broadband white noise. Rise and fall time of PA and PP trials were less than one ms. Five 
interstimulus intervals (ISIs; onset-to-onset) were used for the PP trials: 30, 60, 120, 240, or 2000 ms 
(PP30, PP60, PP120, PP240, PP2000). The initial trial was a PA-115 trial that was separated for 
further analyses. The first and last block of a session consisted of four PA-115 trials and was used for 
the calculation of habituation but not of PPI. The two middle blocks (second and third block), each 
consisted of four PA-115 trials, four PPA-86 trials, four of each of the PP trials, and four NS trials 
presented in a pseudorandom order. Data were analyzed with the Windows based software 
emgBLINK version 1.2 (CST, Zürich, Switzerland). Before scoring, the EMG was smoothed with a 
time constant of 10 ms. Baseline amplitude was calculated by the mean response amplitude of the first 
50 ms before stimulus onset. Stimulus response amplitudes were assessed as peak response minus 
baseline value of the respective trial. Peak response was defined as the highest reaction in the time-
window between stimulus onset to 150 ms after stimulus onset. Every trial was examined for 
spontaneous eye-blinks and other possible signs of corrupted EMG signal; if present the trial was 
excluded from data analysis, which was the case in 2.5% of all trials. Subjects with error trials > 50% 
were excluded from data analysis. Based on this criterion, two of the 18 participating subjects were 
excluded from analysis only of the startle data. 
As described in detail elsewhere (Quednow et al., 2006b; Quednow et al., 2006c), the following startle 
measures were examined: 1) startle reactivity [mean amplitude of PA-115 trials in the first block]; 2) 
percent habituation [=100×(first block of PA-115 trials–last block of PA-115 trials)/first block of PA-
115 trials); 3) slope of the habituation curve across four blocks of PA-115 trials [b=(nΣxy–(Σx)( 
Σy))/(nΣx2–(Σx)2), where x=block number, y=startle amplitude of PA trials per block]; 4) percent PPI 
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and percent prepulse facilitation (PPF) [=100×(PA-115 trials–PP trials)/PA-115 trials]; 5) reactivity to 
prepulse stimuli and NS condition [mean amplitude of PPA-86 and NS trials each within the second 
and third block]; and 6) peak response latency [mean latency to maximal response amplitude occurring 
within 150 ms after PA-115 trials]. 
 
Psychometric Measures 
On the screening day, all subjects completed the FPI (Fahrenberg et al., 1984), which measured nine 
personality traits, and the SCL-90 (Derogatis, 1977), which assessed nine symptom clusters, a global 
severity index (GSI), a positive symptom distress index (PSDI) and a positive symptom total score 
(PST). On each experimental day all subjects completed the AMRS (Janke and Debus, 1978) twice, 
which assessed seven mood subscales. At the end of each experimental day, all subjects completed the 
List of Complaints (von Zerssen, 1971) consisting of 65 common psychosomatic symptoms which 
were summed for a total score. 
 
Neuropsychological test Battery 
The battery comprises of the German version of the Rey Auditory Verbal Learning Test (RAVLT) 
(Helmstaedter et al., 2001; Rey, 1958) and six tests of the Cambridge Neuropsychological Test 
Automated Battery (CANTAB, www.cantab.com), which were performed on an IBM-compatible 
personal computer with a touch-screen monitor (Elo IntelliTouch, Ottobrunn, Germany). 
RAVLT: This task measures verbal declarative memory performance with regard to the supraspan (trial 
1), learning performance (Σ trials 1-5), recall of interference list (list B), recall after interference (trial 
6), delayed recall (trial 7 after 30 min), loss after consolidation (trial 5 minus trial 7), and adjusted 
recognition performance (p(list A)). Administration of the RAVLT and calculation of the several 
parameters have been described in detail elsewhere (Quednow et al., 2006a).  
CANTAB: The Motor Screening Task (MOT) was used to introduce the subjects to the touch-screen 
procedure by touching the center point of flashing crosses on the screen as soon as possible after 
appearance. The response latency was assessed. The Rapid Visual Information Processing Task (RVP) 
is a visual continuous performance task using predefined sequences of three digits presented at a rate 
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of 100 per minute to assess sustained attention over a period of four min. Sustained attention 
performance was assessed by total correct responses to target sequences (total hits), discrimination 
performance (A’) and latency to hit responses. The Intra/Extradimensional Attentional Set Shifting 
Task (ID/ED) is a test for rule acquisition and reversal, featuring visual discrimination and attentional 
set-shifting, analogous to the Wisconsin Card Sorting Task (Heaton, 1981). Performance was assessed 
by the number of trials (adjusted to the number of completed stages), the total number of errors 
(adjusted to the number of completed stages), the errors made up to the extra-dimensional shift (Pre-
ED errors) and the errors made at the extra-dimensional stage of the task (ED errors). The Stockings of 
Cambridge Task (SOC) measures the subject's spatial planning ability, based upon the Tower of 
London Task (Shallice, 1982). The total number of problems solved in the minimum number of 
moves, the number of moves to reach criterion, initial thinking time and subsequent thinking time 
were all assessed. The Spatial Recognition Memory Task (SRM) proves visual spatial memory in a 2-
choice forced discrimination paradigm. Performance was indexed by the mean latency to correct 
responses, and percent of correct hits of a maximum of 20. Finally, the Spatial Working Memory Task 
(SWM) tests spatial working memory and strategy performance. The subject had to find a blue 'token' 
in each displayed box, whilst not returning to boxes in which a blue token had already been found. 
Performance was indexed by a strategy score, which represents the number of times the subject begins 
a new search with the same box. A high score represents poor use of this strategy and a low score 
equates to effective use. Furthermore, the total number of errors and between errors (searching a token 
in a box where one had already been found) was assessed. 
 
Statistical Analysis  
All data were analyzed by SPSS 12.0 for Windows. Startle data, psychometrical data and 
neuropsychological data were analyzed by analyses of variance (ANOVA) with repeated 
measurements. Based on significant main effects, Least Significant Difference (LSD) post-hoc 
comparisons were performed (in case of graded within-subject factors). Frequency differences within 
single complaints were analyzed by McNemar tests. Interrelationships between startle parameter, 
psychometrical scales, neuropsychological variables, and demographic data were tested using 
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Pearson’s product-moment-correlation. The confirmatory statistical comparisons were carried out at a 
significance level set at p<.05 (2-tailed). Within the correlation analyses, the significance level was set 
at p<.01 (2-tailed) in order to avoid accumulation of α-error. Finally, effect sizes were calculated with 
G*Power 3 (Faul et al., 2007) according to the conventions of Cohen (1988).  
 
 
Results 
Startle Measurements 
A 4x2 (ISI condition x treatment) repeated measurement ANOVA with the four PPI conditions (PP30, 
PP60, PP120, PP240) revealed significant main effects for the factors treatment [F(1,45)=6.04; p<.05] 
and ISI condition [F(3,45)=24.97; p<.001] but no significant interaction of both factors. LSD post-hoc 
tests revealed that morphine significantly increased PPI in the PP60 [p<.05, d=0.55] and in the PP240 
condition [p<.05, d=0.54] (see Figure 1). A repeated measurement ANOVA with the PPF condition 
PP2000 did not show a significant drug effect. 
 
******* Insert Figure 1 ******* 
 
Given that the PPI-enhancing effects of clozapine in healthy volunteers is limited to subjects with low 
PPI levels (Vollenweider et al., 2006) we investigated the influence of placebo PPI levels on the drug 
effects. We divided the sample into low vs. high PPI groups by median split in the PP60 and PP240 
PPI condition each. Then we calculated a 2x2 (group x treatment) repeated measurement ANOVA 
with both corresponding PPI conditions separately. While we found significant main effects for the 
factors treatment [FPP60(1,14)=4.61; p<.05; FPP240(1,14)=5.22; p<.001] and group [FPP60(1,14)=30.12; 
p<.001; FPP240(1,14)=19.27; p<.001] we could not detect significant interactions of both factors in both 
PP conditions. Thus, the drug effect was not limited to subjects with low PPI. 
Morphine did not alter startle reactivity, habituation, peak response latency, reactivity to prepulse 
stimuli and amplitude in NS trials (see Table 2). Finally, reactivity to prepulse stimuli (PPA-86) and 
to NS trials did not differ significantly. 
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******* Insert Table 2 ******* 
 
AMRS, List of Complains, and Cardiovascular Measures 
The AMRS subscales were analyzed with 2x2 (treatment x rating) repeated measurement ANOVAs 
(see Table 3 showing the AMRS change scores between the baseline rating and the rating 70 min after 
drug/placebo intake). No significant treatment x rating interaction and no significant main effect of the 
factor treatment occurred. A significant main effect of the factor rating could be shown only for the 
AMRS subscales performance-related activity [F(1,17)=7.09; p<.05] and general inactivation 
[F(1,17)=5.17; p<.05], indicating a decrease of general activity across both test sessions. However, 
there were only weak statistical trends for an increase of anxiety-depression and dreaminess under 
morphine (see Table 3). 
 
******* Insert Table 3 ******* 
 
The rate (±SD) of side-effects – measured with the List of Complaints – did not significantly differ 
between placebo (2.06±1.70) and morphine (2.89±3.09) [F(1,17)=1.34; p=.26; d=0.27]. Analyses with 
McNemar tests at item level did not show any significant differences between both drug conditions. In 
sum, Tiredness was the most frequent complaint (mentioned under placebo: 7 times/under morphine: 8 
times) followed by Faintness (4/6) and Addephagia (4/5). 
A 2x2x3 (treatment x systolic vs. diastolic blood pressure x rating) repeated measurement ANOVA of 
the blood pressure ratings did not reveal an impact of morphine on systolic or diastolic blood pressure. 
Moreover, a 2x3 (treatment x rating) repeated measurement ANOVA of the heart rate did also not 
show any influence of the study medication on heart rate (cardiovascular data not shown). 
 
Neuropsychological Data 
Repeated measurement ANOVAs revealed a significant main effect of treatment with respect to the 
pre-extra-dimensional shift errors (pre-ED errors) whereas all other neuropsychological parameters did 
not significantly differ (see Table 4). A 2x9 (treatment x ID/ED stages) repeated measurement 
ANOVA of the error rates across the nine ID/ED stages revealed a significant main effect of the factor 
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stage [F(8,136)=11.4; p<.001] but only a statistical trend for the factor treatment [F(1,136)=2.97; 
p=.09] and no significant interaction of both factors (see Figure 2). For an exploratory approach we 
analyzed the single stages separately by means of LSD post-hoc tests. It turned out that the error rates 
in the first stage Simple discrimination [p<.001, d=0.97] and in the sixth stage Intradimensional shift 
[p<.05, d=0.51] were significantly improved under morphine. 
 
******* Insert Table 4 ******* 
******* Insert Figure 2 ******* 
 
Correlational Analyses 
To assess whether the significant PPI enhancement parallels the significant decrease in the ID/ED pre-
ED error rate we correlated the change-scores of both parameters, which were indeed not significantly 
associated. However, the change score of the error rate in the Simple discrimination stage was 
positively correlated with the change score of the mean %PPI across ISI conditions [r=0.66, p<.01, 
n=16], indicating that subjects with increased PPI also made less errors under morphine. Moreover, 
PPI enhancement (PP30 and PP60 conditions) was significantly correlated with decrease of SOC 
subsequent thinking time [rPP30=-0.63, p<.01, n=16; rPP60=0.64, p<.01, n=16]. 
Interestingly, mean %PPI across ISI conditions at placebo condition was negatively correlated with the 
FPI subscale Inhibition [r=-0.66, p<.01, n=16], reflecting that subjects with low PPI show high social 
inhibition (in the sense of shyness). With exception of a significant correlation between slope of 
habituation curve and verbal IQ [r=-0.67, p<.01, n=16] (pointing that a high IQ goes along with a 
strong habitation capacity) no other demographic variables were significantly correlated with PPI, 
habituation, and startle reactivity. 
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Discussion 
To our knowledge, this is the first study investigating the effects of the μ-opioid receptor agonist 
morphine on sensorimotor gating and attentional set-shifting in healthy human volunteers. The study 
yielded two main results: Firstly, morphine significantly increased PPI across all of the investigated 
ISI conditions without influencing startle reactivity and habituation. The strongest effect sizes 
occurred in the 60 ms and 240 ms ISI condition. The PPI-enhancing effect was seen in most of the 
subjects and was not limited to subjects with low PPI as shown previously for the atypical 
antipsychotics clozapine and quetiapine (Swerdlow et al., 2006; Vollenweider et al., 2006). Secondly, 
morphine selectively improved the Pre-extradimensional (Pre-ED) error-rate in the ID/ED Task but 
did not significantly affect other neuropsychological domains such as vigilance, memory, or executive 
functions. Interestingly, the PPI improvement (summed across conditions) was associated with the 
decrease of errors at the first stage (Simple discrimination) of the ID/ED Task. Moreover, at the 
relatively low dose morphine did not significantly affect mood and did not cause more side-effects 
than placebo. 
 
The morphine-induced increase of PPI in our healthy volunteers is in line with the previously reported 
increase of PPI by heroin in rats (Swerdlow et al., 1991). Furthermore, morphine did not alter startle 
amplitude or habituation which is also in accordance with previous studies (Leitner, 1989; Ouagazzal 
et al., 2001; Swerdlow et al., 1991). Some previous studies also reported PPI-improving effects of 
psychoactive drugs in healthy human volunteers: nicotine increased PPI in smokers and non-smokers 
(Kumari et al., 1997; Postma et al., 2006), clozapine and quetiapine enhanced PPI in subjects 
exhibiting low PPI levels (Swerdlow et al., 2006; Vollenweider et al., 2006), and the serotonin releaser 
MDMA (Vollenweider et al., 1999), as well as the hallucinogenic serotonin-2A/1A agonist psilocybin 
increased PPI exclusively at long ISIs (Gouzoulis-Mayfrank et al., 1998; Vollenweider et al., 2007). 
How could the PPI-enhancing effect of morphine be explained? The opioid-system interacts with 
several neurotransmitter systems such as dopamine, glutamate, GABA, acetylcholine, and substance P 
within core regions critically involved in sensorimotor gating such as nucleus accumbens (NAc), 
ventral pallidum (VP), and ventral tegmental area (VTA) (McGehee, 2006; Napier and Mitrovic, 
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1999; Pan, 1998; Swerdlow et al., 2001; Xi and Stein, 2002). Since Ukai and Okuda (2003) have 
shown that the μ-opioid receptor agonist endomorphin-1 could inhibit the apomorphine-induced PPI 
deficit in mice and as it has been found that naloxone could prevent amphetamine-induced disruption 
of PPI in rats (Swerdlow et al., 1991) one could speculate that opiate-dopamine interactions may 
account for the PPI-increasing effect of morphine. This would also fit with the hypothesis that opioid-
dopamine interactions play a role in the pathogenesis of schizophrenia (Schmauss and Emrich, 1985). 
However, μ-opioid receptor agonists such as morphine disinhibit dopaminergic neurons in the VTA 
through inhibition of GABAergic interneurons and increase dopamine release in the NAc, an effect 
which is widely accepted to explain a part of the addictive and rewarding properties of opioids (Koob, 
2000; Pan, 1998; Xi and Stein, 2002). Since it has been consistently shown that even an increase of 
dopamine in the NAc disrupts PPI in rats (for review see Swerdlow et al., 2001), opioid-dopamine 
interactions in the NAc are not very likely to explain the present finding of an μ-opioid receptor-
mediated increase of PPI. Even the finding of Bortolato et al (2005) that κ-opioid receptor activation 
disrupts PPI does not support dopamine-opioid interactions as an explanation of opioid induced PPI 
alterations because κ-opioid receptor activation decreases dopamine release in the NAc (Pan, 1998). 
However, μ-opioid receptor agonists are also modulating GABAergic and glutamatergic 
neurotransmission in the VP and VTA (Johnson and Napier, 1997; Mitrovic and Napier, 2002; Napier 
and Mitrovic, 1999; Xi and Stein, 2002) and these neurotransmitter systems have been shown as 
critically involved in the processing of PPI in these regions (for review see Swerdlow et al., 2001). 
Moreover, evidence from behavioral and in vitro electrophysiological studies suggests that μ-opioid 
receptors interact with serotonin-2A receptors in the medial prefrontal cortex (MPFC) (Domino, 1986; 
Marek, 2003; Marek and Aghajanian, 1998a; Marek and Aghajanian, 1998b; Marek et al., 2001), and 
serotonergic activity in the cortex (and in the VP) has been demonstrated to be an important substrate 
of PPI-modulation in rats (Geyer et al., 2001; Sipes and Geyer, 1997; Swerdlow et al., 2001). With 
regard to the present findings it should be noted that especially low doses of μ-opioid receptor agonists 
antagonized behavioral effects of hallucinogens mainly acting on serotonin-2A receptors, whereas 
larger doses rather enhance these effects (Domino, 1986). In addition, it has been shown that even 
subthreshold doses of morphine can strongly modulate other dopaminergic, GABAergic or 
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glutamatergic neurotransmissions in the VTA, VP and NAc (Napier and Mitrovic, 1999). Thus, larger 
doses of morphine may loose the ability to increase PPI, which would explain the finding that high 
doses of morphine did not change PPI in rats (Leitner, 1989; Ouagazzal et al., 2001). 
Given the facts that activation of nicotinic acetylcholine receptors can increase PPI (Kumari et al., 
1997; Postma et al., 2006) and that μ-opioid receptor activation can also modulate acetylcholine 
release in the NAc (McGehee, 2006), it is also conceivable that nicotinic-opioid receptor interactions 
may contribute to the PPI increase under morphine. 
Finally, it is an interesting conjunction that the κ-opioid receptor agonist U50488 disrupts PPI 
(Bortolato et al., 2005) whereas we found a PPI-enhancing effect following μ-opioid receptor 
activation. These findings are in accordance with the hypothesis that activation of κ-opioid receptors 
antagonize various μ-opioid receptor-mediated actions in the brain (Pan, 1998). 
It should be noted that previous animal studies investigating the effects of morphine on PPI mostly 
applied only a single ISI of 100 ms and that we found the strongest effects at lead intervals of 60 and 
240 ms. Furthermore, the sample sizes of these animal studies were generally smaller (n=8-12) than in 
our investigation (Leitner, 1989; Ouagazzal et al., 2001; Swerdlow et al., 1991). Therefore, differences 
in ISI, sample size, and morphine dose (see above) or unknown species-specific mechanisms could 
possibly account for the fact that previous animal studies did not detect a significant increase of PPI 
under morphine. 
In conclusion, the PPI-enhancing effect of morphine could be possibly be mediated by interactions 
between μ-opioid receptors and glutamatergic, GABAergic or nicotinic innervations of the VP or VTA 
or by interactions with the serotonin system within the MPFC or VP. However, animal studies are 
needed to explore these supposed neurotransmitter interactions in more detail.  
Given that PPI-enhancing effects are seen as an indicator of antipsychotic activity (Swerdlow and 
Geyer, 1998) the present findings raise the question whether morphine could have antipsychotic 
properties. Interestingly, morphine is to be regarded as the first specific antipsychotic in the history of 
psychopharmacology. It was widely used for the treatment of affective and psychotic disorders until it 
fell into disfavor by the beginning of the 19th century because of its addictive potential (Comfort, 
1977). An observation by Comfort (1977) could also point toward antipsychotic activity: “...a clinical 
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impression remains, unsupported by any good figures, that among addicts there are some who would 
have become psychotic if not addicted, and who use morphinoids (heroin in particular) to hold at bay 
intolerable prepsychotic sensations, and that these are sharply exacerbated by withdrawal” (p. 448). 
In the 1970s a possible involvement of endogenous opioids in the pathogenesis of schizophrenia was 
proposed (Bloom et al., 1976; Jacquet and Marks, 1976; Terenius et al., 1976), but following clinical 
studies with opioid agonists and antagonists did not reveal marked clinical effectiveness of these 
substances in schizophrenia patients (for review see Schmauss and Emrich, 1985). However, from the 
current perspective these studies suffered from small sample sizes, short observation periods and lack 
of placebo control. Taken together, our findings suggest that the μ-opioid receptor may possibly be an 
interesting drug target for the treatment of schizophrenia. 
With regard to the self-medication hypothesis of addictive disorders (Khantzian, 1985) our findings 
raise a further question: Do opioid addicts have PPI deficits? Surprisingly, there are no PPI data of 
opioid addicts available so far and it would be of great interest to learn whether PPI is decreased in 
these patients and what happens with PPI during withdrawal and when opioids are administered. 
 
The data further show that morphine reduces the Pre-ED error-rate in the ID/ED Task, especially in 
the stages Simple discrimination (SDI) stage and Intradimensional shift (ID). The error rate during the 
Extradimensional shift (ED) was not significantly improved, albeit also decreased, while reversal 
learning was unaffected by morphine. Whereas the SDI stage requires only visual discrimination 
learning, in the ID stage subjects have to learn the transfer of a rule within the same perceptual 
dimension (e.g. shape). By contrast, the ED stage requires the shift to a new – previously irrelevant – 
perceptual dimension (e.g color) while the previously attended feature must be disregarded (Owen et 
al., 1991). It has been consistently reported that schizophrenia patients display deficits in the ID and 
ED stages of the ID/ED Task (Elliott et al., 1995; Hutton et al., 1998; Jazbec et al., 2007; Pantelis et 
al., 1999). These previous studies primarily investigated the attrition rate and the trials to reach 
criterion as dependent variables and these parameters were not significantly affected by morphine in 
the present study (data not shown). However, it has been shown that schizophrenia patients committed 
more errors especially in the SDI and ID stages rather than in the ED stage (Pantelis et al., 1999) and 
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errors on the ID stage were associated with disorganized symptom characteristics of schizophrenia 
(Pantelis et al., 2004). Moreover, abstinent heroin abusers also showed significant impairment of 
performance at the ID but not at the ED stage (Ornstein et al., 2000). Lesion studies and studies with 
patients suffering from Parkinson’s or Huntington’s disease suggest that the prefrontal cortex and the 
basal ganglia are involved in performing ED shifts (Dias et al., 1996; Downes et al., 1989; Lawrence 
et al., 1996; Owen et al., 1992; Owen et al., 1991). The ability to reverse stimulus-reward connections 
within a perceptual dimension (reversal learning), on the other hand, is more associated with the 
orbitofrontal cortex (Dias et al., 1996). 
The involvement of the opioid system in attentional set-shifting is scarcely investigated. A recent 
study reported that the mixed μ-, δ-, and κ-opioid receptor antagonist naltrexone attenuated the 
impairment in ED shifts in aged rats (Rodefer and Nguyen, 2006) but studies in humans are lacking. 
Nevertheless, our finding is in line with previous studies showing morphine-induced improvement of 
neuropsychological performance in tests supposedly involving similar attentional processes like visual 
discrimination learning such as choice reaction time tasks (Hanks et al., 1995; O'Neill et al., 2000) and 
perceptual and semantic evaluation tasks (Evans and Smith, 1964). The idea that morphine could 
improve cognition is not new. Based on self-experiments examining the effect of morphine on choice 
reaction tasks, Kraepelin (1892) already concluded that morphine “immediately facilitates the 
perception of external stimuli, … , whereas the implementation of choice is aggravated in the same 
time” [“… (Morphin) erleichtert … sofort die Auffassung äusserer Eindrücke, … , während die 
Ausführung des Wahlactes in ganz ähnlichem Tempo erschwert wird” p. 255]. 
A further important result is that the morphine-induced increase in PPI was correlated with the 
decrease of the error-rate within the SDI stage of the ID/ED Task. The SDI stage measures alertness 
rather than rule acquisition like later stages of the task (Jazbec et al., 2007). This correlation is in 
accordance with our previous observation that psilocybin-induced deficits of sustained attention 
deficits were associated with PPI reduction at short ISI intervals (Vollenweider et al., 2007). These 
findings support the hypothesis that deficits in sensorimotor gating may underlie the more complex 
attentional and cognitive abnormalities in schizophrenia (Braff et al., 2001). Since we have shown that 
morphine enhance PPI and attentional set-shifting – processes that are both impaired in schizophrenia 
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– the μ-opioid receptor might be a promising target for the development of specific cognitive 
enhancers for schizophrenia patients. Furthermore, abstinent opiate addicts also show worse 
performance at the ID stage and morphine specifically improves this kind of visual discrimination 
learning what might support the self-medication hypothesis of opiate addiction (Khantzian, 1985). It 
would be of interest if opiate addicts receiving heroin substitution would show improved ID 
performance compared to abstinent subjects. 
In conclusion our findings imply that the μ-opioid system is involved in the modulation of PPI and 
attentional set-shifting. These results raise the question whether the opioid system plays a crucial role 
also in the regulation of PPI and attentional set-shifting in schizophrenia in which both functions were 
shown as deficient. Future preclinical studies should evaluate if μ-opioid receptors could be a potential 
drug target for new antipsychotic agents or cognitive enhancers for schizophrenic patients. Moreover, 
animal studies are needed to enlighten the anatomical structures and neurochemical mechanisms 
underlying the morphine-induced increase of PPI and attentional set-shifting in our healthy human 
volunteers. 
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Figure Legends 
 
Figure 1: Prepulse inhibition (PPI; interstimulus intervals (ISI): 30-240 ms) and Prepulse Facilitation 
(PPF; ISI 2000 ms) of acoustic startle response under morphine and placebo (means and standard error 
of means). PPI is improved after 10 mg morphine sulfate (LSD post-hoc tests: *p<.05). 
 
Figure 2: Error rates across the nine stages of the Intra/Extradimensional Attentional Set Shifting 
Task (ID/ED) of the Cambridge Neuropsychological Test Automated Battery (CANTAB) (means and 
standard error of means). Morphine decrease the error rate in the first stage Simple discrimination and 
in the sixth stage Intradimensional shift (LSD post-hoc tests: *p<.05; ***p<.001). 
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Table 1: Demographic and psychometric data of the 18 healthy human volunteers 
 Mean (± SD) 
Age 23.9 (±2.9) 
Weight (kg) 73.8 (±7.2) 
Height (m) 1.80 (±0.1) 
Body Mass Index (BMI) 22.8 (±1.4) 
Verbal IQ 104.5 (±11.0) 
SCL-90  
Somatisation 0.26 (±0.28) 
Obsessive compulsion 0.53 (±0.45) 
Interpersonal sensitivity 0.33 (±0.48) 
Depression 0.31 (±0.43) 
Anxiety 0.18 (±0.26) 
Hostility 0.33 (±0.49) 
Phobic anxiety 0.06 (±0.14) 
Paranoid ideation 0.36 (±0.46) 
Psychoticism 0.17 (±0.37) 
Positive symptom total  19.0 (±15.5) 
Global severity index 0.29 (±0.32) 
Positive symptom distress index 1.25 (±0.28) 
FPI  
Nervousness 3.35 (±2.60) 
Aggression 3.61 (±2.55) 
Depression 2.82 (±2.72) 
Excitability 2.47 (±2.10) 
Sociability 9.35 (±2.83) 
Patience 5.06(±2.05) 
Dominance 2.47 (±1.74) 
Inhibition 3.18 (±2.21) 
Frankness 4.88 (±1.36) 
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Table 2 Means and standard deviation of means (in parentheses) of the amplitude of 115 dB-pulse-alone (PA-115) trials in the first block (startle 
reactivity), the amplitude of 86 dB-prepulse-alone (PPA-86) trials (reactivity to prepulse stimuli), the amplitude in no-stimulus (NS) trials, 
the percent prepulse inhibition (PPI) summed across ISI conditions (PP30-PP240), the percent habituation between first and last block of 
PA-115 trials, the slope of the habituation curve, and the latency of startle response peak in PA-115 trials under placebo and 10 mg 
morphine sulfate in 16 healthy volunteers. 
 
Startle measures Placebo Morphine Effect size d F df,dferror p 
Mean amplitude of PA-115 trials (first block) 
(Arbitrary units) 
543.0 
(±383.1) 
549.8 
(±376.2) 0.04 
 
0.02 
 
1,15 0.89 
Mean amplitude of PPA-86 trials 
(Arbitrary units) 25.7 (±55.0) 22.8 (±33.0) 0.08 
 
0.11 
 
1,15 0.75 
Mean amplitude of NS trials  
(Arbitrary units) 8.8 (±3.3) 10.6 (±6.8) 0.26 
 
1.15 
 
1,15 0.30 
Mean Σ percent PPI 
(PP30-PP240 conditions) 37.2 (±20.5) 46.3 (±20.1) 0.61 
 
6.04 
 
1,15 0.03 
Mean percent habituation of PA-115 trials 
(between first and last block) 50.3 (±26.7) 53.7 (±21.3) 0.12 
 
0.24 
 
1,15 0.63 
Habituation of PA-115 trials across 4 blocks 
(linear gradient coefficient b) -87.6 (±73.6) -93.4 (±58.9) 0.08 
 
0.11 
 
1,15 0.74 
Mean peak response latency 
(milliseconds) 64.3 (±8.1) 67.2 (±15.1) 0.21 
 
0.68 
 
1,15 0.42 
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Table 3 Means and standard deviation of means (in parentheses) of the change scores (baseline scores minus scores 70 min after drug/placebo 
intake) of the subscales of the Adjective Mood Rating Scale (AMRS) under placebo and 10 mg morphine sulfate in 18 healthy volunteers. 
 
AMRS subscales Placebo Morphine Effect size d F df,dferror p 
Performance-related activity 1.33 (±2.87) 2.11 (±3.56) 0.23 
 
0.93 
 
1,17 0.35 
General inactivation -1.39 (±3.36) -2.22 (±5.64) 0.13 
 
0.31 
 
1,17 0.59 
Extroversion-introversion -0.11 (±1.60) 1.00 (±2.81) 0.33 
 
1.93 
 
1,17 0.18 
General well-being 0.17 (±1.72) 0.94 (±2.55) 0.23 
 
0.95 
 
1,17 0.34 
Emotional excitability -0.06 (±1.80) -0.11 (±1.23) 0.02 
 
0.01 
 
1,17 0.92 
Anxiety-depresssion 0.33 (±1.19) -0.50 (±1.69) 0.35 
 
2.25 
 
1,17 0.15 
Dreaminess 0.00 (±0.77) -0.67 (±1.75) 0.38 
 
2.62 
 
1,17 0.12 
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Table 4 Means and standard deviation of means (in parentheses) of RAVLT variables and CANTAB task scores under placebo and 10 mg 
morphine sulfate in 18 healthy volunteers. 
Tests Placebo Morphine Effect size d F df,dferror p 
RAVLT       
Supraspan (trial 1) 10.8 (±2.29) 11.1 (±2.00) 0.12 0.33 1,17 0.57 
Learning performance (Σ trials 1-5) 67.3 (±6.59) 67.4 (±7.29) 0.04 0.03 1,17 0.87 
Recall of interference list (list B) 11.4 (±2.57) 10.7 (±2.47) 0.32 1.91 1,17 0.19 
Recall after interference list (trial 6) 13.9 (±1.86) 13.6 (±2.15) 0.20 0.90 1,17 0.36 
Delayed recall (trial 7) 13.8 (±1.86) 13.1 (±3.19) 0.30 1.78 1,17 0.20 
Loss after consolidation (trial 5 minus 7) 0.78 (±1.35) 1.33 (±2.11) 0.31 1.80 1,17 0.20 
Adjusted recognition performance p(A) 0.93 (±0.07) 0.92 (±0.13) 0.10 0.05 1,17 0.83 
       
CANTAB       
Motor Screening (MOT)       
Response latency (ms) 654 (±81.3) 671 (±125.5) 0.17 0.53 1,17 0.48 
Rapid Visual Information Processing (RVP)       
Total Hits 21.4 (±2.99) 21.2 (±4.37) 0.07 0.06 1,17 0.81 
Discrimination performance (A’) 0.95 (±0.03) 0.95 (±0.04) 0.06 0.05 1,17 0.82 
Response latency (ms) 434 (±68.6) 456 (±114.9) 0.29 1.57 1,17 0.23 
ID/ED Attentional Set Shifting (ID/ED)       
Total trials (adjusted) 72.4 (±11.1) 67.9 (±7.2) 0.35 2.16 1,17 0.16 
Total errors (adjusted) 12.6 (±5.64) 9.6 (±4.29) 0.42 3.23 1,17 0.09 
Pre-ED errors 7.2 (±1.76) 5.3 (±1.57) 0.88 13.81 1,17 0.002 
ED errors 3.6 (±4.19) 2.1 (±1.28) 0.34 2.12 1,17 0.16 
Stockings of Cambridge (SOC)       
Problems solved in minimum moves 9.8 (±1.44) 9.7 (±1.28) 0.07 0.10 1,17 0.76 
Moves to reach criterion 4.0 (±0.32) 4.0 (±0.31) 0.03 0.02 1,17 0.90 
Initial thinking time (ms) 5065 (±2625) 5304 (±2415) 0.08 0.12 1,17 0.74 
Subsequent thinking time (ms) 192 (±245.9) 212 (±196.9) 0.07 0.08 1,17 0.78 
Spatial Recognition Memory       
Response latency (ms) 1961 (±568.4) 2094 (±574.8) 0.22 0.85 1,17 0.37 
Percent correct hits 83.6 (±10.5) 85.8 (±6.47) 0.21 0.81 1,17 0.38 
Spatial Working Memory (SWM)       
Strategy score 26.7 (±6.59) 25.8 (±5.22) 0.20 0.72 1,17 0.41 
Total number of errors 6.2 (±6.01) 5.6 (±6.90) 0.07 0.09 1,17 0.77 
Between errors 5.9 (±5.81) 5.4 (±6.97) 0.06 0.05 1,17 0.83 
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